Literature DB >> 21351527

[Expressions of survivin and GRIM-19 in prostate cancer].

Yan-bo Liu1, Wei-gao Shen, He Ge, Xiao-dong Gai, Li-li Lu, Xue-jian Zhao.   

Abstract

OBJECTIVE: To investigate the expressions of survivin and GRIM-19 in prostatic cancer tissue and their clinical implications.
METHODS: We detected the expressions of survivin and GRIM-19 in the tissues of normal prostate (NP), benign prostate hyperplasia (BPH) and prostate cancer (PCa) using immunohistochemical staining, RT-PCR and Western blot, and processed the data by SPSS12.
RESULTS: The positive rates of survivin expression were 6.25% , 18.18% and 90.62% in NP, BPH and PCa (P < 0.01), while those of GRIM-19 were 87.50%, 81.82% and 9.37% , respectively (P < 0.01). Semiquantitative RT-PCR and immunohistochemical staining showed that both survivin mRNA and survivin expressions were highly positive in PCa but negative in NP and BPH. Western blot exhibited that the survivin protein was expressed strongly in PCa but weakly in NP and BPH, while the GRIM-19 protein was expressed just contrariwise (P < 0.01).
CONCLUSION: The expressions of survivin and GRIM-19 may be closely correlated with the pathogenesis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21351527

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  3 in total

Review 1.  GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  Cytokine Growth Factor Rev       Date:  2016-09-15       Impact factor: 7.638

2.  GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.

Authors:  S Kalakonda; S C Nallar; D J Lindner; P Sun; R R Lorenz; E Lamarre; S P Reddy; D V Kalvakolanu
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

3.  Serum survivin increases in prolactinoma.

Authors:  Fatma Dilek Dellal; Mutlu Niyazoglu; Suheyla Gorar; Esranur Ademoglu; Zehra Candan; Handan Bekdemir; Yalcin Hacioglu; Fatih Oner Kaya
Journal:  J Clin Med Res       Date:  2015-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.